Evolving Considerations in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca, Bayer Healthcare, and Merck Sharp & Dohme Corp.

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 142,670 deaths from lung cancer in 2019, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets, especially around EGFR mutation–positive NSCLC. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. The expanding role of these therapies and the concept of tailoring therapies based on clinical and molecular markers are transforming the treatment of NSCLC.

Upon completion of this activity, participants will be able to:

  • Discuss the latest recommendations for tissue- and blood-based molecular testing to evaluate EGFR mutation status in patients with advanced non-small cell lung cancer (NSCLC)

  • Compare current and emerging first-line treatment strategies for advanced EGFR-mutated advanced NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors

  • Explore current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated advanced NSCLC

  • Analyze evidence of efficacy in delaying or reducing brain metastases for the different EGFR TKIs in patients with advanced NSCLC

  • Evaluate managed care considerations on optimizing the use of targeted therapy in advanced EGFR-mutated advanced NSCLC, managing therapy-related toxicities, improving adherence, expanding payer/provider communication, and aiding in the implementation of clinical pathways to deliver quality care

  • Transform therapeutic advances and resource utilization data in EGFR-mutated advanced NSCLC into informed health plan decisions and formulary discussions

Faculty: Eric H. Bernicker, MD
Associate Professor of Clinical Medicine
Houston Institute for Academic Medicine
Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Houston Methodist Cancer Center


Dr. Bernicker has served on an advisory board for BMS and Guardant Health. He has received grant/research support from Genentech. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca, Bayer Healthcare, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue